Back D J, Bates M, Bowden A, Breckenridge A M, Hall M J, Jones H, MacIver M, Orme M, Perucca E, Richens A, Rowe P H, Smith E
Contraception. 1980 Nov;22(5):495-503. doi: 10.1016/0010-7824(80)90102-x.
In a group of 5 women on long-term anticonvulsant and oral contraceptive therapy, the plasma ethynylestradiol (EE) concentration on 50 microgram EE daily was 11.1 +/- 4.5 pg/ml. These values were at the lower end of the range found in normal women in this laboratory taking 30 microgram EE daily (6-190 pg/ml). Four women have been studied prospectively for 3 months, over 1 cycle before and 2 cycles during phenobarbital 30 mg b.i.d. therapy. Significant falls in the plasma EE concentration were seen in two women (from 104.8 +/- 13.4 to 37.7 +/- 2.0 pg/ml and from 125.6 +/- 23.8 to 34.8 +/- 6.7 pg/ml p less than 0.01) and breakthrough bleeding was seen in both women. No changes in plasma concentrations of follicle stimulating hormone, progesterone, norethindrone or norgestrel were seen. There was a significant increase in the sex hormone binding globulin capacity from 100.7 +/- 5.8 to 133.3 +/- 1.2 nmoles/1 (p less than 0.05). These changes are consistent with the known microsomal enzyme inducing effect of phenobarbital.
在一组5名接受长期抗惊厥药和口服避孕药治疗的女性中，每日服用50微克炔雌醇（EE）时，血浆炔雌醇浓度为11.1±4.5皮克/毫升。这些值处于本实验室中每日服用30微克EE的正常女性所测得范围的下限（6 - 190皮克/毫升）。对4名女性进行了为期3个月的前瞻性研究，在苯巴比妥每日30毫克、每日两次治疗前1个周期及治疗期间2个周期进行观察。两名女性的血浆EE浓度显著下降（分别从104.8±13.4降至37.7±2.0皮克/毫升，以及从125.6±23.8降至34.8±6.7皮克/毫升，p<0.01），且两名女性均出现突破性出血。卵泡刺激素、孕酮、炔诺酮或左炔诺孕酮的血浆浓度未见变化。性激素结合球蛋白结合能力从100.7±5.8显著增加至133.3±1.2纳摩尔/升（p<0.05）。这些变化与苯巴比妥已知的微粒体酶诱导作用相符。
